Immunotherapeutic activity of a recombinant combined gB-gD-gE vaccine against recurrent HSV-2 infections in a guinea pig model

Roberto Manservigi, Anna Boero, Rafaela Argnani, Elisabetta Caselli, Silvia Zucchini, Vivì Miriagou, Penelope Mavromara, Michele Cilli, Maria Pia Grossi, Pier Giorgio Balboni, Enzo Cassai

Research output: Contribution to journalArticlepeer-review

Abstract

The guinea pig model of recurrent genital herpes simplex virus type 2 (HSV-2) infection was used to test the immunotherapeutic activity of a glycoprotein subunit vaccine. Vaccine formulation consisted of three recombinant herpes simplex virus (HSV) glycoproteins, namely gB1s, gD2t and gE1t, plus aluminium hydroxide [Al(OH) 3)] adjuvant. One month after viral challenge, infected animals were therapeutically immunised by seven subcutaneous injections of a low dose of antigens with a weekly interval for the first five and a fortnightly interval for the last two administrations. Results showed that the treatment was highly effective in ameliorating the recidivist pathology of animals, suggesting that this kind of vaccine formulation and administration may be helpful for therapeutic intervention in humans affected by recurrent herpes infections.

Original languageEnglish
Pages (from-to)865-872
Number of pages8
JournalVaccine
Volume23
Issue number7
DOIs
Publication statusPublished - Jan 4 2005

Keywords

  • Herpes simplex virus vaccine
  • Immunotherapy
  • Viral glycoproteins

ASJC Scopus subject areas

  • Immunology
  • Microbiology
  • Virology
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)

Fingerprint Dive into the research topics of 'Immunotherapeutic activity of a recombinant combined gB-gD-gE vaccine against recurrent HSV-2 infections in a guinea pig model'. Together they form a unique fingerprint.

Cite this